Teva’s Orange Book Patent Dispute: Implications for the Pharmaceutical Industry

In a significant move within the pharmaceutical industry, Israeli drugmaker Teva is seeking to have the full Federal Circuit hear a case regarding the delisting of patents from the U.S. Food and Drug Administration’s Orange Book. The branded pharmaceutical sector is rallying behind Teva’s legal effort, emphasizing the case’s potential impact on patent listings and drug regulation. For more details on this legal development, visit the coverage by Law360.